Navigation Links
HeartWare Reports Second Quarter 2012 Results
Date:8/7/2012

tion therapy from the FDA," added Mr. Godshall.  "Our second quarter results also reflect increased investment in our technology pipeline, particularly our MVAD® System for which human clinical testing is expected this year, as well as ramping of personnel in anticipation of expanded commercialization."

Total operating expenses for the second quarter of 2012 were $34.2 million, as compared to $20.2 million in the same period of 2011.  Research and development expense was $20.0 million for the second quarter of 2012, as compared to $10.3 million in the same period of 2011, primarily attributable to the Company's continuing clinical trial costs and research and development costs related to advancing HeartWare's pipeline technologies.  Selling, general and administrative expenses were $14.2 million in the second quarter of 2012, compared to $9.9 million in the second quarter of 2011.  The increase in selling, general and administrative expenses is related to a higher volume of commercial activity outside of the U.S. and an enhanced corporate infrastructure to support overall growth and anticipated commercialization in the U.S.

Net loss for the second quarter of 2012 was $22.8 million, or a $1.61 loss per basic and diluted share, compared to a $10.1 million net loss, or a loss of $0.73 per basic and diluted share, in the second quarter of 2011.  For the six months ended June 30, 2012, the Company recorded a net loss of $41.6 million, or a $2.94 loss per basic and diluted share, compared to a $19.5 million net loss, or a loss of $1.40 per basic and diluted share, in the first half of 2011.

At June 30, 2012, the Company had $131.0 million of cash, cash equivalents and investments, as compared to $144.5 million at March 31, 2012 and $163.2 million at December 31, 2011.

HeartWare will host a conference call on Tuesday, August 7, 2012 at 5:00 p.m. U.S. Eastern Daylight Time (being 7:00 a.m. Australian Ea
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. HeartWare Completes Acquisition Of World Heart Corporation
2. HeartWare Schedules Second Quarter Conference Call And Webcast
3. HeartWare Names Peter F. McAree Chief Financial Officer
4. HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart Failure
5. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
6. HeartWare Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference to be Webcast
7. Heartware Schedules First Quarter Conference Call And Webcast
8. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Express Scripts Reports Second Quarter Results
11. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 ACIST Medical ... market leader of advanced imaging modalities for cardiology, showcased ... in two live cases at the Transcatheter Cardiovascular Therapeutics ... cases were presented from Medstar Washington Hospital Center ( ... University Medical Center ( New York, NY ...
(Date:9/17/2014)... N.J. , Sept. 17, 2014  Bayer HealthCare ... National Hemophilia Foundation,s 66 th Annual Meeting, which ... , D.C.  The data, which will be shared through ... treatment and patient care. Data will be presented in ... research into treatment modalities in hemophilia A patients, Bayer ...
(Date:9/17/2014)... 2014   MedeAnalytics today unveils Revenue ... complete visibility to a provider,s "mid-cycle" to optimize ... landscape. Powered by the industry,s leading big data ... point between patient access and the business office ... improve revenue capture, minimize audit risk and prepare ...
Breaking Medicine Technology:ACIST Launches HDi High-Definition IVUS 2ACIST Launches HDi High-Definition IVUS 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3
... Mich., Oct. 19, 2011 Perrigo Company (Nasdaq: PRGO;TASE) ... agreement with Founder Pharma Co., Ltd., a wholly owned ... (SZSE: 000788).  Perrigo will supply infant formula manufactured in ... Pharma in China. Perrigo Chairman and CEO ...
... N.Y., Oct. 19, 2011  CureFAKtor Pharmaceuticals, LLC, a privately-held ... Focal Adhesion Kinase (FAK) inhibitors for cancer, announced today ... will present a company overview at the Biotechnology Industry ... San Francisco, CA on Wednesday, October 26 at 9:00 ...
Cached Medicine Technology:Perrigo Expands Infant Formula Distribution in China With Founder Group 2CureFAKtor Pharmaceuticals to Present at 10th Annual BIO Investor Forum 2
(Date:9/17/2014)... A new, first-of-its-kind research study was announced today ... lifestyle can impact long-term wellness and contribute to ... Prevention Research Center and funded through a $10 ... Institute Wellness Fund, WELL aims to identify lifestyle ... their health and wellness as they age. WELL ...
(Date:9/17/2014)... that guard against damage to the ends of chromosomes could ... the deadliest form of skin cancer according to ... study has uncovered an important new genetic risk factor for ... count are the strongest indicators of those most at risk ... care in the sun, as they burn more easily. , ...
(Date:9/17/2014)... 2014 Catalent Pharma Solutions, the ... development solutions for drugs, biologics and consumer health ... integrated service and technology offer based on the ... the company’s 450,000 sq. ft. Kansas City, MO ... integrate optimal formulation, development, analytical expertise, scale up ...
(Date:9/17/2014)... The Scripps Research Institute (TSRI) have devised a ... effective against vancomycin-resistant strains of MRSA and other ... to have not one but two distinct mechanisms ... evolve resistance quickly. , "This is the prototype ... in clinical use a generation or maybe even ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Boston ... to create a monthly concert series, introducing young ... From the Top, America’s premier national platform celebrating ... musicians. Many of the young musicians featured will ... , “Boston Children’s Museum is fortunate to partner ...
Breaking Medicine News(10 mins):Health News:First-ever research study examines impacts of diet and lifestyle on healthy aging 2Health News:Chromosome buffers hold key to better melanoma understanding 2Health News:New OptiPact™ Technology Introduced by Catalent 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 3Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 3
... New York City Department of,Health recently released a study ... obesity increased 17% over a two year period. With ... that they are,drinking sugar sweetened drinks with many calories, ... by drinking TrimWater, (http://www.trimwater.com )., TrimWater is a ...
... 29, 2008) Pauletta and Denzel Washington will present ... High School in Denzels hometown of Mount Vernon, N.Y. ... Pauletta and Denzel Washington Family Scholar in Neuroscience Awards ... of Neurosurgery at Cedars-Sinai Medical Center in Los Angeles. ...
... of Queensland-based Astute Nanotechnology will celebrate the,achievements ... a special presentation and cocktail,reception tomorrow Tuesday, ... for industry partners to access the,expertise and ... of Excellence for Functional,Nanomaterials (ARC CFN). , ...
... 30 AMDL, Inc. (Amex:,ADL), headquartered in ... Jilin, China, is a vertically integrated specialty,pharmaceutical ... Inc., (JPI), the Company engages in the ... supplement, and cosmetic products., AMDL today ...
... Psychemedics,Corporation (Amex: PMD ) today announced first ... The Company also announced a quarterly,dividend of $0.17 per ... 6,2008 to be paid on June 20, 2008. This ... Company,s revenue for the quarter ended March 31, 2008 ...
... Anthem,s Care Comparison Tool Gives Members in Wisconsin the ... Picture of Costs Associated with Medical Procedures, ... Blue Shield,in Wisconsin announced today the launch of its ... now nearly 3 million Anthem Blue Cross and Blue ...
Cached Medicine News:Health News:Time for New Yorkers to Drink Low-Calorie, Low-Sugar Flavored Water, TrimWater 2Health News:Denzel Washington's hometown hosts awarding of scholarships bearing Washington family name 2Health News:Denzel Washington's hometown hosts awarding of scholarships bearing Washington family name 3Health News:Astute Nanotechnology celebrates first year of success 2Health News:Astute Nanotechnology celebrates first year of success 3Health News:AMDL Signs MOU for 200 Store Distribution Arrangements for Goodnak Product Line 2Health News:Psychemedics Corporation Announces First Quarter Results 2Health News:Psychemedics Corporation Announces First Quarter Results 3Health News:Psychemedics Corporation Announces First Quarter Results 4Health News:Psychemedics Corporation Announces First Quarter Results 5Health News:Anthem Blue Cross and Blue Shield Introduces Industry's Most Comprehensive Transparency Initiative to Wisconsin 2Health News:Anthem Blue Cross and Blue Shield Introduces Industry's Most Comprehensive Transparency Initiative to Wisconsin 3
Plus cylinders only trial lens set....
This is a reduced form of the 100 Hue test and is obviously quicker to administer. It provides extensive chromatic sensitivity and gives a quantitative score. Kit includes 100 score pads....
... test (P/N LD15C) include a durable laminated ... P/N LD15C also includes a Plexiglas Case ... for the test subjects fingers ( to ... discs). Beware that these finger cots are ...
Opti-One multi-purpose solution with citrate protein removal and advanced surfactant combination....
Medicine Products: